📊 ABUS Key Takeaways
Is Arbutus Biopharma Corp (ABUS) a Good Investment?
Strong revenue growth (+128% YoY) and pristine balance sheet with zero debt are offset by severe earnings quality concerns: the $178M gap between reported net income ($169.7M) and negative operating cash flow (-$8.1M) indicates non-recurring items are inflating profitability, while the 94.7% net margin is extraordinarily high for pharma and unsustainable.
Arbutus Biopharma's fundamentals are weak: revenue fell 66% year over year, operating and net margins are deeply negative, and operating cash flow remains meaningfully negative. The balance sheet is a mitigating factor, with high liquidity, no long-term debt, and positive equity, but the current financial profile still depends on preserving cash while improving pipeline-related monetization or partnership revenue.
Arbutus Biopharma Corp Key Strengths (ABUS)
- Exceptional revenue growth of 128% YoY indicating strong commercial momentum
- Pristine balance sheet with zero long-term debt and $260.2M stockholders equity
- Exceptional ROE (65.2%) and ROA (61.2%) on reported earnings basis
- Very strong liquidity with 18.80x current and quick ratios
- Debt-free capital structure with no long-term debt
- Positive stockholders' equity of $77.40M provides balance sheet cushion
ABUS Stock Risks: Arbutus Biopharma Corp Investment Risks
- Severe earnings quality concerns: $178M divergence between net income and operating cash flow indicates non-cash gains, milestone payments, or deferred revenue are inflating profits
- Extraordinarily high profit margins (94.7% net, 94.3% operating) are unsustainable for pharma and likely driven by one-time items
- Negative operating cash flow with only $23.7M cash balance creates sustainability risk despite apparent profitability
- Revenue is highly unstable, with a 66.0% year-over-year decline
- Severe and persistent losses shown by -252.2% operating margin and -228.2% net margin
- Heavy cash burn with -$34.96M operating cash flow and free cash flow pressures financial runway
Key Metrics to Watch
- Operating cash flow trend and underlying drivers of net income to assess earnings quality
- Breakdown of revenue by source (product sales vs. milestone payments vs. licensing) to identify recurring vs. non-recurring
- Cash position trajectory and burn rate given negative OCF despite reported profitability
- Quarterly operating cash burn relative to cash and equivalents
- Revenue durability and any improvement in operating loss trend
Arbutus Biopharma Corp (ABUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 54.26x current ratio provides a solid financial cushion.
ABUS Profit Margin, ROE & Profitability Analysis
ABUS vs Healthcare Sector: How Arbutus Biopharma Corp Compares
How Arbutus Biopharma Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arbutus Biopharma Corp Stock Overvalued? ABUS Valuation Analysis 2026
Based on fundamental analysis, Arbutus Biopharma Corp appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arbutus Biopharma Corp Balance Sheet: ABUS Debt, Cash & Liquidity
ABUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arbutus Biopharma Corp's revenue has grown significantly by 28% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.38 indicates the company is currently unprofitable.
ABUS Revenue Growth, EPS Growth & YoY Performance
ABUS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.8M | -$24.5M | $-0.13 |
| Q3 2025 | $529.0K | $2.5M | $-0.04 |
| Q2 2025 | $1.7M | $2.5M | $0.01 |
| Q1 2025 | $1.5M | -$17.9M | $-0.10 |
| Q3 2024 | $1.3M | -$16.3M | $-0.10 |
| Q2 2024 | $1.7M | -$16.3M | $-0.10 |
| Q1 2024 | $1.5M | -$16.3M | $-0.10 |
| Q3 2023 | $4.7M | -$14.2M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arbutus Biopharma Corp Dividends, Buybacks & Capital Allocation
ABUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arbutus Biopharma Corp (CIK: 0001447028)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABUS
What is the AI rating for ABUS?
Arbutus Biopharma Corp (ABUS) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABUS's key strengths?
Claude: Exceptional revenue growth of 128% YoY indicating strong commercial momentum. Pristine balance sheet with zero long-term debt and $260.2M stockholders equity. ChatGPT: Very strong liquidity with 18.80x current and quick ratios. Debt-free capital structure with no long-term debt.
What are the risks of investing in ABUS?
Claude: Severe earnings quality concerns: $178M divergence between net income and operating cash flow indicates non-cash gains, milestone payments, or deferred revenue are inflating profits. Extraordinarily high profit margins (94.7% net, 94.3% operating) are unsustainable for pharma and likely driven by one-time items. ChatGPT: Revenue is highly unstable, with a 66.0% year-over-year decline. Severe and persistent losses shown by -252.2% operating margin and -228.2% net margin.
What is ABUS's revenue and growth?
Arbutus Biopharma Corp reported revenue of $179.1M.
Does ABUS pay dividends?
Arbutus Biopharma Corp does not currently pay dividends.
Where can I find ABUS SEC filings?
Official SEC filings for Arbutus Biopharma Corp (CIK: 0001447028) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABUS's EPS?
Arbutus Biopharma Corp has a diluted EPS of $0.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ABUS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Arbutus Biopharma Corp has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ABUS stock overvalued or undervalued?
Valuation metrics for ABUS: ROE of 65.2% (sector avg: 15%), net margin of 94.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is ABUS's AI grade for 2026?
Our dual AI analysis gives Arbutus Biopharma Corp a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ABUS's free cash flow?
Arbutus Biopharma Corp's operating cash flow is $-8.1M, with capital expenditures of $0.0. FCF margin is -4.5%.
How does ABUS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 94.7% (avg: 12%), ROE 65.2% (avg: 15%), current ratio 54.26 (avg: 2).
Why is ABUS's return on equity (ROE) so high?
Arbutus Biopharma Corp has a return on equity of 65.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 94.7% net margin.